WGNV seeks to support and facilitate TB vaccine R&D and to advance the vaccine-related objectives in the Global Plan to End TB by conducting activities in the following priority areas.


WGNV implements projects and programs that support TB vaccine research literacy among advocates and affected communities, as well as supporting advocacy literacy among researchers. WGNV also engages in global advocacy efforts as a member of the Core Group of the TB Vaccine Advocacy Roadmap (TBVaxARM).

Learn more about advocacy opportunities on the Take Action page of this website.

Supporting Early Career Researchers

WGNV supports an Early Career Researcher (ECR) Network, which coordinates activities to support and engage ECRs. These may include virtual networking sessions, online and in-person networking opportunities, workshops and talk to the experts sessions on topics that are important to ECRs, and opportunities to raise the visibility of ECRs in the TB vaccine R&D space.

Learn more about the Early Career Researcher Network here.


WGNV shares knowledge and information about TB vaccine R&D in various ways, including convening the Global Forum on TB Vaccines series, organizing workshops, compiling a pipeline of TB vaccine candidates in development, and sharing resources and information through its website.

Issues in Product Development

WGNV recognizes the challenges in translating concepts for novel TB vaccines into potential products. To help address this challenge, WGNV provides resources and information on product development and is developing a platform for researchers to connect with each other and with potential partners and collaborators.

Learn more about resources for product development here.

Fostering Discussion

WGNV seeks to provide a platform for discussion on key issues, concepts, and gaps in TB vaccine R&D through activities such as workshops and consensus statements.

Past Workshops
13 - 14 June 2023: Recognizing the Mtb-infected cell: From basics to the clinic (co-hosted with the National Institute for Allergy and Infectious Diseases (NIAID))